1.
N Engl J Med
; 388(19): e72, 2023 May 11.
Article
in English
| MEDLINE | ID: covidwho-2318744
2.
N Engl J Med
; 387(23): e73, 2022 12 08.
Article
in English
| MEDLINE | ID: covidwho-2310698
3.
N Engl J Med
; 387(16): e47, 2022 10 20.
Article
in English
| MEDLINE | ID: covidwho-2310702
4.
N Engl J Med
; 386(17): e53, 2022 04 28.
Article
in English
| MEDLINE | ID: covidwho-2310701
5.
N Engl J Med
; 387(2): e10, 2022 07 14.
Article
in English
| MEDLINE | ID: covidwho-2310700
6.
N Engl J Med
; 387(20): e60, 2022 11 17.
Article
in English
| MEDLINE | ID: covidwho-2310699
7.
N Engl J Med
; 388(15): e64, 2023 Apr 13.
Article
in English
| MEDLINE | ID: covidwho-2302798
8.
Lancet Reg Health West Pac
; 14: 100274, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-2250512
9.
N Engl J Med
; 382(19): 1851-1852, 2020 05 07.
Article
in English
| MEDLINE | ID: covidwho-2250809
10.
N Engl J Med
; 388(11): e39, 2023 Mar 16.
Article
in English
| MEDLINE | ID: covidwho-2278952
Subject(s)
Biomedical Research , COVID-19 , Humans , SARS-CoV-2 , Biomedical Research/trends , Forecasting
11.
N Engl J Med
; 388(13): e53, 2023 Mar 30.
Article
in English
| MEDLINE | ID: covidwho-2278951
12.
N Engl J Med
; 388(9): e36, 2023 Mar 02.
Article
in English
| MEDLINE | ID: covidwho-2278949
13.
N Engl J Med
; 387(19): e56, 2022 11 10.
Article
in English
| MEDLINE | ID: covidwho-2278948
14.
N Engl J Med
; 388(2): e8, 2023 01 12.
Article
in English
| MEDLINE | ID: covidwho-2244722
15.
N Engl J Med
; 388(7): e23, 2023 Feb 16.
Article
in English
| MEDLINE | ID: covidwho-2244721
16.
N Engl J Med
; 382(22): e94, 2020 05 28.
Article
in English
| MEDLINE | ID: covidwho-2227810
Subject(s)
Adenosine Monophosphate/analogs & derivatives , Alanine/analogs & derivatives , Antiviral Agents/therapeutic use , Betacoronavirus , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Adenosine Monophosphate/administration & dosage , Adenosine Monophosphate/adverse effects , Adenosine Monophosphate/supply & distribution , Adenosine Monophosphate/therapeutic use , Adult , Alanine/administration & dosage , Alanine/adverse effects , Alanine/supply & distribution , Alanine/therapeutic use , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Antiviral Agents/supply & distribution , COVID-19 , Coronavirus Infections/mortality , Coronavirus Infections/virology , Drug Administration Schedule , Drug Evaluation , Humans , Hydroxychloroquine/adverse effects , Hydroxychloroquine/therapeutic use , Infusions, Intravenous , Pandemics , Placebos , Pneumonia, Viral/mortality , Pneumonia, Viral/virology , Randomized Controlled Trials as Topic , SARS-CoV-2 , Time Factors , Treatment Outcome , Viral Load/drug effects
17.
N Engl J Med
; 387(9): e24, 2022 09 01.
Article
in English
| MEDLINE | ID: covidwho-2235061
18.
N Engl J Med
; 387(10): e26, 2022 09 08.
Article
in English
| MEDLINE | ID: covidwho-2235060
19.
N Engl J Med
; 387(8): e22, 2022 08 25.
Article
in English
| MEDLINE | ID: covidwho-2235059
20.
N Engl J Med
; 388(5): e21, 2023 02 02.
Article
in English
| MEDLINE | ID: covidwho-2222052